Needham Ups Encysive Pharmaceuticals to 'Buy'

Analyst Mark Monane doesn't think the current valuation reflects the market potential for the drugmaker's hypertension treatment

Needham upgraded Encysive Pharmaceuticals (ENCY ) to buy from hold.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.